Tagged with Linical

Research Arnaud Lagesse, CEO of GML, the largest company in Mauritius and the third largest company in the Indian Ocean, discusses his company’s successful diversification into the life sciences sector, with the creation of GML Life. The history of GML has always been linked to the development of the Mauritian economy.…

manufacturing The chancellor of the Medical Sciences Campus of the University of Puerto Rico discusses the medical R&D projects the university is currently involved in, the fields in which the island has the most potential, and how the institution is tailoring its academic offer to suit the local needs of the…

clinical trials ACLIRES’ senior vice president explains the organization’s ambitions to promote Thailand as a unique place for early phase studies, the company’s partnership with Mahidol University and Siriraj Hospital and its dedication to the development of medicine for Thailand, the region and the world.   What brought you to work at ACLIRES?…

CRO Omega CRO has evolved from its beginnings as a CRO contracted by local and multinational pharmaceutical companies into an organization leading clinical, epidemiological and observational studies of public interest across Turkey. CEO Berk Özdemir discusses the highlights of these studies, including a giant EU 7th Framework project EU-GEI study on…

Parexel Claudio Soto, general manager of PAREXEL Mexico, discusses how the clinical research process required to receive approval for a new clinical protocol in Mexico is fairly straightforward compared to other countries in Latin America. She also addresses the government´s increasing awareness of the importance of their role in helping to…

CRO The directors of one of the leading in country contract research organisations, explain exactly what makes Romania such an attractive destination for clinical trials. They also give some indications of how the already booming clinical research is expected to thrive, and how there will remain plenty of work for all.…

CRO The directors of one of the leading in country contract research organisations, explain exactly what makes Romania such an attractive destination for clinical trials. They also give some indications of how the already booming clinical research is expected to thrive, and how there will remain plenty of work for all.…

CRO The general manager of one of the leading CROs in Romania explains how the country in gathering pace as a top tier clinical trials destination country within the region and how the priority is now about on-time project delivery. Could you please start by introducing PSI and its engagement with…

Janssen The country manager of one of the foremost providers of sustainable and integrated healthcare solutions describes the sorts of local adaptations that need to be enacted when launching a product on the Romanian market. He also speaks extensively about the state of the local medical device market and its likely future potential. Can…

Actelion Turkey has been a high priority market for Actelion since the company’s relatively recent beginnings, and the general manager of the local affiliate discusses his affiliate efforts to improve awareness around this rare disease through open communication with health authorities, and the need for formal recognition of orphan drugs by…

Bayer Bayer Turkey’s healthcare division head discusses how the company adapted to the post 2009 pharmaceutical pricing environment by shrinking their portfolio and focusing strongly on key growth products, launched recently from its R&D pipeline. The affiliate is also focusing on its role as a contributor to Turkish society with R&D,…

hospitals Medipol hospital’s medical director discusses the private institution’s current role in the Turkish healthcare system, and their plans for expansion in the coming years.  How did Medipol come into existence, and where does the hospital stand today? Medipol was opened three years ago, and today the hospital has 500 beds,…